The concentrations of the cell free DNA (cfDNA) and somatic mutations in circulating tumor DNA (ctDNA) in serial samples correlate with the number of days of the progression-free period and with the overall survival.
Age
18–99
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Metastatic breast cancer before the start of chemotherapeutic treatment
You may not be if
Patients with incomplete clinical records
Clareo Health | Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica
